Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR's share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of C$12.26 and traded as low as C$11.03. Cipher Pharmaceuticals shares last traded at C$11.46, with a volume of 12,928 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group set a C$12.50 price objective on shares of Cipher Pharmaceuticals and gave the company a "hold" rating in a research note on Monday, April 7th.
Check Out Our Latest Report on Cipher Pharmaceuticals
Cipher Pharmaceuticals Trading Up 0.8 %
The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00. The stock has a market capitalization of C$213.82 million, a P/E ratio of 13.15 and a beta of 1.20. The business has a 50 day simple moving average of C$12.16 and a 200-day simple moving average of C$13.87.
Insider Activity at Cipher Pharmaceuticals
In other news, Director Harold Morton Wolkin sold 3,500 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of C$13.49, for a total value of C$47,215.00. 42.00% of the stock is currently owned by corporate insiders.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Featured Articles
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
